SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytotekk who wrote (137)5/8/1998 12:22:00 PM
From: Sigmund  Read Replies (2) of 178
 
I couldn't find anything at this link: quote.com
Were you referring to the news on companies reimbursing? Are these new reimbursers? Hope company announces them one at a time from now on.

The point I was trying to make on the 25% not being 25% is that the approval I think calls for 15% rescreening rather than the usual 10%. The 15% is on the 75% and I look at this as job protection rather than really required.

You seen to work at a lab that has the AutoPap now. What percentage of all slides go through the AutoPap now? Is this percentage determined by what can be reimbursed?

I still think that primary screen screws up secondary screening. The AutoPap makes a great secondary screener if it screens all slides. What could be better. But now some other algorithm will be required for selecting slides for secondary screening. I think you were saying high risk cases and random.

Random certainly helps you identify malfunctioning techs. So perhaps it is a good way. But it doesn't provide as good a health benefit as secondary screening by AutoPap. Perhaps you are right though that you take care of that by how you assign the slides in the first place.

But I would still be very concerned about the low risk slides assigned to the low performing techs.

My girlfriend is disabled but used to be a lab director...not in a cytology lab. Earlier in her career when she was a hematology supervisor at the VA she once had a tech who was "vision challenged". That kind of hampers effectiveness. I can imagine that such a tech in a cytology lab would be assigned all of the slides where nothing was expected to be found. So a tech that is ineffective and who believes that there is nothing to be found equals not finding anything. Could be a problem.

Overall though I think it looks good for NPTH. If only they would remove Nelson and bring in someone who knows how to run a company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News